ANZCTR search results

Military personnel returning from overseas deployment often suffer from sleep difficulties. Demanding and altered working hours, challenging environmental conditions, high work tempo, and altered interpersonal and support environments contribute to disturbed sleep during operations. If left untreated, sleep difficulties can lead to poorer mental health outcomes; in fact, sleep complications may become a chronic health issue. The research will evaluate the effectiveness of two treatments. Cognitive Behavioural Therapy for Insomnia (CBT-i) and Bright Light Therapy (BLT) for improving sleep and mental health will be trialed in a sample of 40 ADF personnel.

Dementia is the single greatest cause of disability in older Australians and the third leading cause of disability burden in Australia. Due to our aging population the number of Australians living with dementia is expected to increase rapidly over the next decade placing additional burden on the health system and on the unpaid/family carers of people with dementia. Behavioural changes occur in 90% of people with dementia. These changes are stressful and challenging for carers. The purpose of this study is to examine an online educational training program that teaches carers of people with dementia ways to manage common behaviours. It is expected that the program will reduce carer burden and stress.

This is a double-blind, randomised, placebo-controlled study to evaluate the efficacy of a herbal formulation. The aim is to investigate if the formulation reduces the severity and duration of cold & flu symptoms compared to placebo.

This pilot study will determine the feasibility of a second line combination chemotherapy of NAB-Paclitaxel and capecitabine for the treatment of advance biliary cancer. Who is it for? You may be eligible to join this study if you are aged 18 years or above, have histologically proven unresectable biliary tract cancer and have had prior chemotherapy treatment with gemcitabine/platinum. Study Details: All participants will receive combination chemotherapy using NAB-Paclitaxel and Capecitabine for as long as their disease responds to treatment and will be followed up every 12 weeks (until death) after end of treatment with CT imaging, status and quality of life assessments in order to determine feasibility, clinical benefit, survival rates and impact of treatment on quality of life.

Loss of motor function and shoulder pain are known outcomes of stroke that affect patients’ well being and independence. Physiotherapy routinely uses a variety of approaches to address these issues, including facilitating improved motor activation and better shoulder alignment. Using rigid strapping tape has been shown to have some benefits as an adjunct to treatment however, more recently kinesiology tape which is more flexible has become readily available. This has been used on many patient and athletic groups, but has only been used once in a group with stroke, and this was not at the shoulder. This study aims to determine if kinesiology tape is useful as part of a treatment approach to managing the affected shoulder in acute stroke. Participants will be recruited from admissions to ward G51 at Sir Charles Gairdner Hospital over a period of 4 months. The study will be a single blinded, randomised controlled trial with the control group receiving placebo taping and the intervention group will receive therapeutic taping. Pain, shoulder position, muscle stiffness and range of movement will be recorded every 3 days during the trial to determine how these factors change over time. Measures of motor impairment in the arm will be taken on admission and discharge (or at 14 days, whichever comes first). It is expected that there will be no adverse effects of the taping. It is anticipated there may be some benefit in using the kinesiology tape for shoulder pain and motor activation, however this problem is multifactorial and the effect size is expected to be low. This study is a pilot study to test the protocol and determine effect size with a view to a more extensive study in the future.

The Ripple project concerns young people who are removed from their families of origin because of significant risk of harm and placed in State care. These young people often have multiple and complex needs, poor mental health, high risk of mental disorders and poor social outcomes. The overall aim of the project is to assess whether a mental health intervention that enhances the care roles and capacities of carers in Out of Home Care (OoHC) will improve (i) the consistency and quality of OoHC for all young people (12-17 years) in the OoHC sector, and (ii) access to early intervention when indicated for prevention and treatment of mental illness. Both aims will contribute to improving the mental health of young people living in OoHC.

The Anti-Amyloid Treatment in Asymptomatic Alzheimer’s Disease study (the “A4 study”) is a clinical trial testing an anti-amyloid investigational drug (called solanezumab, also known as LY2062340) in older individuals who have evidence of elevated amyloid build-up in their brains, but who do not yet show symptoms of AD. The primary purpose of this study is to test whether solanezumab can slow possible AD-related damage in the brain and to delay progression of AD-related memory loss associated with brain amyloid.

This study aims to implement and evaluate the feasibility of an integrated care model for prostate cancer patients that incorporates both local and centralised services. You may be eligible to join this study if you are aged 18 years or above and have been diagnosed with localised prostate cancer within the previous 3 months, OR diagnosed with advanced prostate cancer for at least 12 months. All patients in this study will be provided with local and centralised prostate cancer support services. These include Care Coordination, Information Provision and Decision Support, Practical Support, Peer Support, Lifestyle Plan, Speialised Support Services, and Advanced Prostate Cancer Comorbidities Management. While each component of the intervention is available for all participants, the intervention and each of its components are tailored to the patient’s stage of disease and their health related needs. Delivery of specialised support services will depend on resource availabililty, access, treating specialist /team preference and preference of the patient. Patients in this study will be asked to complete 3 surveys over a 6 month period (at the commencement of participation, followed by 3 and 6 months after the commencement of participation) in order to assess their quality of life, prostate cancer symptoms and mental health. In addition, service and carer-related outcomes will be measured. At 6 months after the commencement of participation, patients, carers and key personnel involved in delivering the intervention will be invited to complete an online survey and participate in individual interviews. This is a pilot study focused on determining feasiblity of a larger randomised study. If the intervention is effective, men with prostate cancer will have access to evidence based supportive care interventions that will contributed to improved health outcomes and quality of life.

The aim of the 6 year allergy follow up is to see if taking fish oil supplements during pregnancy can reduce the development of allergies in children and how long these effects may last. At 1 year of age, we found that there were fewer children with atopic eczema and fewer children with a positive skin prick test to egg in the group whose mothers took fish oil supplements during pregnancy than those in the control group that took vegetable oil capsules. As children reach school age we expect asthma and hayfever to become more common and by examining all children at 6 years of age, we will be able see whether the effects of fish oil supplementation during pregnancy are long standing or are only seen in early childhood.

Perhexiline is medication known to improve the efficiency of energy used by the heart. It works by reducing fatty acid and thereby improving glucose utilisation by the heart. The hypothesis of the current study is that perhexiline administration reduces pro-inflammatory markers, and improves insulin sensitivity. Analysis will be performed before and after perhexiline therapy in the diabetic patients, and further analysis will be performed to evaluate the extent of changes in the presence or absence of a type of commonly used heart medication in the diabetics (ACE-inhibitors).